chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Information has been received from a newspaper article regarding a case in litigation concerning a 7 year old male who was vaccinated on 1/25/00 at a pediatric clinic with a dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live. It was reported that after receiving the vaccine, he became a quadriplegic. The reporter noted that he is expected to have a normal life span. And therefore will require more years of care. It was note that the patient will need round the clock care, including extensive medical intervention, throughout his life. At the time of this report, the patient had not recovered. No further information is available. Quadriplegia was considered to be an other important medical event (OMIC). Additional information is not expected.
15min p/vax pt was playfully getting ready to ride home-became limp & unresponsive;sl clonic activity of one hand, out for less than 1min;voided;returned to office acted post-ictal 30min;later vomited x1;BP & vitals stable;no resp distress;
Body rash, right upper quadrant pain, lip swelling, seen ED 7/18/14 rx with prednisone, famotidine and hydroxyzine. Dx by ED with allergic reaction and atypical pain.
pericarditis after second vaccination with pfizer. pt revaccinated due to  new HIV status. had J&J vaccination 4/2021
This spontaneous report as received from a consumer refers to a male patient of unknown age. On an unknown date in 2013 the patient was vaccinated with a dose of ZOSTAVAX (lot#, expiration date dose, route, indication not reported). On 10-SEP-2013 the patient experienced arm hurt for a couple of days after he got his ZOSTAVAX injection. The outcome of the event was unknown. Additional information has been requested.
A non-serious, spontaneous report of administration to pregnant female was received from a Registered Nurse concerning a 40-year-old female. The patient's medical history and obstetrical history were not reported. There was no adverse event experienced to date. Treatment and reporter causality assessments are not applicable. The reporter was asked to inform when the pregnancy has ended and also to inform if the patient experiences any adverse events during the pregnancy.
This spontaneous report was received from a registered nurse refers to a patient (age and gender unknown) with hemophilia. On 17-DEC-1999, the patient was vaccinated with first dose of RECOMBIVAX HB subcutaneously (lot number and dose not reported). On 04-MAY-2000, the patient was vaccinated with second dose of RECOMBIVAX HB subcutaneously (lot number and dose not reported). On 27-AUG-2002, the patient was vaccinated with third dose of RECOMBIVAX HB subcutaneously (lot number and dose not reported). Other suspect therapies included on 07-NOV-2001, the patient was vaccinated with first dose of VAQTA subcutaneously (lot number and dose not provided). On 15-MAY-2002, the patient was vaccinated with second dose of VAQTA (lot number and dose not provided). No concomitant medications were reported. No adverse symptoms were reported. Additional information has been requested.
Patient came in to pharmacy on 4-30-17 w/redness and itching at the vaccination site. It presented the day after vaccination and has gotten larger in the past day.
This spontaneous report was received from a pharmacist and refers to a two unspecified patients of unknown age and gender. There was no information about the patients' concurrent conditions, concomitant therapies or medical history provided. On 10-MAR-2017, the patients were vaccinated with an expired dose of ZOSTAVAX 1 DS x 1 vial, lot # L046900 with an expiration date 23-FEB-2017 for prophylaxis (dose and route of administration were not reported). No side effects was reported. There was no product quality complaint involved. Additional information has been requested.
Swelling of nodes in lower left part of the neck, the doctor prescribed Tylex 750 mg 3 times a day for 5 days.
right arm where the patient received the first dose was really sore; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (right arm where the patient received the first dose was really sore) in a 35-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026C21A) for COVID-19 vaccination.     No Medical History information was reported.    On 09-Aug-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced VACCINATION SITE PAIN (right arm where the patient received the first dose was really sore). At the time of the report, VACCINATION SITE PAIN (right arm where the patient received the first dose was really sore) outcome was unknown.        mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) dosing remained unchanged.       No concomitant medications were reported.  Treatment information included cold medicine that helped the patient to get sleep like nightquil. The patient drunk lot's of fluids.  Patient's date of birth was 1985.   This case was linked to MOD-2021-310671 (Patient Link).
Information has been received from a physician concerninga 5 year old female Caucasian patient with no relevant medical history and no known allergies who on 9/1/99 was vaccinated with a first dose of varicella virus vaccine live, only, lot number no available. It was unknown if illness was present at the time of vaccination. The child developed chicken pox described as 20 lesions, which was vesicular, pruritic and crusted over within 48 hours and no other symptoms were noted. There was no relevant diagnostic data. It was noted that the physician stated that this case was the most like a typical varicella case. Unspecified medical attention was sought. on 3/14/03, the patient recovered. There was no product quality complaint involved. The physician also reported on two other siblings that developed chicken pox. No further information is expected.
Acid reflux, flu-like aches & pains, headache, slight fever for 4 days (so far)
I basically had somewhat of a runny nose but also had somewhat of a stuffy nose.  In general a tiredness.  No aches. No fever.  No difficulty breathing.
12-days p/receiving flu c/o h/a, chills, achy joints, nausea, tiredness; 4NOV h/a excruciating, pain, stiffness lt side neck lasting & finally subsided 19NOV93; MD felt either viral meningitis or caused by flu shot;
Hospital admission following months of abnormal uterine bleeding post vaccination Abnormal uterine bleeding (AUB) [N93.9]
Patient was given FLUBLOCK which is an influenza vaccine not in range for her age at the time of vaccination.  Patient's mother did not report any adverse reaction when she was contacted by our office. S
hives; swelling; itchiness; redness; 18 x 14 cm rash on injection site arm; This spontaneous case was reported by a consumer and describes the occurrence of URTICARIA (hives), SWELLING (swelling), PRURITUS (itchiness), ERYTHEMA (redness) and VACCINATION SITE RASH (18 x 14 cm rash on injection site arm) in a 56-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 014M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 26-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 07-Mar-2021, the patient experienced URTICARIA (hives), SWELLING (swelling), PRURITUS (itchiness), ERYTHEMA (redness) and VACCINATION SITE RASH (18 x 14 cm rash on injection site arm). The patient was treated with DIPHENHYDRAMINE HYDROCHLORIDE (BENADRYL [DIPHENHYDRAMINE HYDROCHLORIDE]) at a dose of 1 dosage form and CALAMINE, GLYCEROL, ZINC OXIDE (CALAMINE LOTION) at an unspecified dose and frequency. At the time of the report, URTICARIA (hives), PRURITUS (itchiness), ERYTHEMA (redness) and VACCINATION SITE RASH (18 x 14 cm rash on injection site arm) outcome was unknown and SWELLING (swelling) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were provided.
Having a reaction; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION REACTION (Having a reaction) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 prophylaxis.     Concurrent medical conditions included Egg allergy.    On 24-Jun-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In June 2022, the patient experienced IMMUNISATION REACTION (Having a reaction). At the time of the report, IMMUNISATION REACTION (Having a reaction) outcome was unknown.            No concomitant medications was reported. No treatment drug details was reported. The patient took the Moderna booster dose. It was reported that the patient wants to know if the reaction was produced in an egg base.
10 hrs after shot uncontrollable shaking & frezzing cold.  5 hrs later really bad muscle pain in hips & legs.  Couldnt stand up. 24hs Later symptoms gone.
T-102F 11/13/01. ER 11/14/01 18:00 T-105F, P 148, R 32, O2 sat 96%, course rhonchi, runny nose, pulls ears. Completed Amoxil 11/14/01. Impression: Fever, OM, Tonsillitis, Feverall 120mg supp, Rocaphin 500mg IM
symptoms cough and muscle aches starting on 12/20/21, covid positive on 12/21/21.
15 hours after vaccination, severe body aches, chills, fever up to 101.9 (baseline 96), sweats, fatigue, these symptoms for 46 hours. Then nausea, headache, light headed on day 4. I had Covid pneumonia June 2020.
Aching injection site; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Aching injection site) in a 34-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 011620A) for COVID-19 vaccination.     No medical history was provided by the reporter.  Concomitant products included SIMVASTATIN, LEVOTHYROXINE, PREDNISONE, PARACETAMOL (ACETAMINOPHEN), BUSPIRONE and CHLORTALIDONE (CHLORTHALIDONE) for an unknown indication.    On 14-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 14-Jan-2021, the patient experienced VACCINATION SITE PAIN (Aching injection site). On 14-Jan-2021, VACCINATION SITE PAIN (Aching injection site) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Treatment information was unknown
Around June, I started coughing. When I would talk or when I laugh, I had to cough, when I was drinking water, I would just cough. I couldn't clear my throat. And when I sing, I get a little short of breath. Around the later part of August, I started wheezing, especially at night. I would cough a lot at night. I was not sleeping well because of the coughing. I went to the doctor, the later part of September and he gave me medication for the wheezing, Breztri, 3 puffs BD for 2 weeks and he gave me an antibiotic, Cephalexin 500 mg, 1 capsule, 3 x day for 7 days. And that cleared me up. Sometimes the stuff I would cough would be yellow.
FACIAL/LIP SWELLING 15 MINUTES AFTER 1ST DOSE OF PFIZER COVID VACCINE. IMMEDIATELY  WENT TO ED FOR EVALUATION. ED PHYSICIAN CLINICAL IMPRESSION: MILD ALLERGIC REACTION , NO ANGIOEDEMA,  REATION RESOLVED   NO TREATMENT OTHER THAN EXAMINATION  SYMPTOMS RESOLVED 40 MINUTES.
Chills; Body aches/sore; fatigue; Headache; Loss if appetite; Fever; This is a spontaneous report from a contactable consumer (patient). A 43-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number EN6203 and expiry date not reported), via an unspecified route of administration, administered in Arm Left on 23Mar2021 15:00 (at the age of 43-year-old), as dose 2, single, for COVID-19 immunisation in  clinic. Patient was not pregnant at the time of vaccination. Patient had no allergies to medications, food, or other products. Medical history included obesity. Concomitant medications included probiotics and multivitamins [vitamins nos]. Historical vaccine included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, Solution for injection; lot number EN6203 and expiry date not reported), via an unspecified route of administration, administered in Arm Left on 02Mar2021 13:15 (at the age of 43-year-old), as dose 1, single, for COVID-19 immunisation in  clinic and experienced swelling at injection site, redness at injection site and pain at injection site. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient experienced chills, body aches/sore, fatigue, headache (feels like a sinus headache) that presents when stand up or move, loss of appetite, and fever on 24Mar2021 08:00 AM. No treatment was received for the events. The outcome for the events was recovered.  No follow-up attempts are needed. No further information is expected.
Developed fatigue, body aches, headache 1 day after vaccination on 3/3. The morning of 3/5 complained of chest pain. Took Tylenol at 8:30 am. At 10:30 am his family found him unresponsive. EMS was called and he was pronounced dead in the home.
Report 20000301551 describes viral looking rash in an eight year old female who received Engerix-B for prophylaxis of hepatitis B. Allergies are not specified. The vaccinee's medical history includes several viral rashes. She takes no concomitant medications. On 06/26/2000, the vaccinee received her first IM right deltoid dose of Engerix-B. 24-72 hours later, she developed a "viral looking rash" and fever. Her symptoms resolved. On 08/01/2000, the vaccinee received her second IM right deltoid dose of Engerix-B. 24-72 hours later, she again developed a "viral looking rash" and fever. Her symptoms resolved. No treatment was given. As of 09/29/2000, the outcome of the events is resolved.
TOOK VIVOTIF WITH FOOD; This spontaneous case report was received from a consumer (PVX2019-266) on 29-Jan-2019. The report describes a female consumer who "took Vivotif with food". The consumer was receiving oral Vivotif (one dose every other day) for typhoid fever prophylaxis.  It was reported that the consumer completed the course of Vivotif. She believed that she snacked and may have consumed food before waiting the two hours after taking Vivotif.  The action taken with Vivotif with respect to the event "took Vivotif with food" was not applicable.  The clinical outcome of the event "took Vivotif with food" unknown.  Company's Comment: The causality of the event "took Vivotif with food" was considered as not applicable.; Sender's Comments: Company's Comment: The causality of the event "took Vivotif with food" was considered as not applicable.
Pt presented with AMS. History provided by father at bedside. For 2 days after vaccine pt reported not knowing what he was doing and where he was. Father brought him to ED after having breakfast together and son didn't know how to pay or what foods he liked. Was unable to recall his father's name.  Treatment: DAPT with ASA and plavix x21 days and then transition to plavix 75mg daily, atorvastatin 80mg (stroke treatment) Outcome: TBD
Child brought into health department due to 50mm by 60mm edematous, reddened area, circumscribed left deltoid. Warm to touch. Denies pain or difficulty movement.
Patient is beyond 42 days for second Moderna vaccine; This spontaneous case was reported by a physician and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient is beyond 42 days for second Moderna vaccine) in a male patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 01-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 15-Apr-2021, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient is beyond 42 days for second Moderna vaccine). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Patient is beyond 42 days for second Moderna vaccine) outcome was unknown.      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine)  was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.
Patient received very first vaccine and was a bit anxious.  Patient reported muscle pain in upper arm, right deltoid.  Reported has flashes and stomach pain.  Patient was assessed with relaxation techniques.  Patient retuned to home.
The first reaction I had was inflammation in my ankle during the beginning of my spring break. Four months later the inflammation spread throughout my body. In the summer of 2008 I was given antibiotics to help reduce the swelling. My joints and muscles hurt. Especially when it is cold. Through diet, physical exercises which my then sport doctor gave, and getting 12 hours of sleep a night while my body was recovering I was able to somewhat regain and maintain my health. In the fall of 2009 it felt as if my muscles were being eaten. I took glucosamine to counter that. A couple of years later I developed severe allergies that I received shots for. I never had acne until after the vaccine. My dermatologist office says that I first started being treated for acne in September of 2009. My immune system is easily compromised, which was previously relatively strong. At times I have severe fatigue and need several more hours of sleep to be able to function. Whenever it is cold or I don't get at least 8 hours of sleep I feel pressure in the back of my head, sometimes on the side(s) and top of my head. This pressure makes me not be able to think clearly. It is like being in a daze and not being able to use or retrieve your knowledge. As a result I am not as intelligent as I once was. Thanks to my extremely healthy diet and lifestyle I am able to manage and somewhat succeed.
Initial report received from a health care professional on 25 May 2010: This patient was vaccinated with MENVEO (batch no: 02701), 0.5 ml, intramuscular, on 25 May 2010. The patient was administered with lyophilized MenA CRM component diluted in sterile water instead of the MenCWY liquid component. No adverse events were noted.
Heart palpitations/pounding immediately, over next 48 hours-feeling like I?m going to pass out & developing hives all over body.
The patient received the vaccine on 4/18/21 at 12:56pm. As he was waiting 15-minute post-administration, he walked to the front, (~1 minute post-administration) and fainted. He was caught by his girlfriend and brought down to the floor, where he remained sitting. No injuries reported, reported no nausea, was oriented, held a normal conversation, reported being hot, temp was 95.5F. Paper towel soaked in cold water was applied to forehead, and gave him water to drink. Declined juice. The patient mentioned he had a reaction to a flu vaccine in the past where he was very ill after. He expressed a fear of needles, and he has fainted after bloodwork previously. EMS evaluated, patient declined hospital visit.
This spontaneous report as received from a registered nurse refers to an unspecified number of patients of unknown age and gender. On unspecified dates, since 23-OCT-2014, the patients were vaccinated with ROTATEQ (dose number, route, lot # and expiration date were not provided). In 2014, doses of ROTATEQ that were exposed to a supported temperature excursion (0.2 C for 55 hours) had been administered to unspecified patients on unspecified date, since 23-OCT-2014. No adverse effects had been observed or reported. It was unknown if the patients sought medical attention. At the time of the report, the patients status was unknown. This is one of several reports received from the same source. Additional information has been requested.
Left arm was very soar on 11/18/2021  The same day I noticed under my left armpit swelling and it is very soar. I am waiting to see if these symptoms go away. If the symptoms do not go away I will follow up with my primary care doctor.
Patient developed severe itching and subsequent rash of right upper arm and injection site 1 week post injection.  She also is experiencing malaise, muscle pain and fatigue.
Patient awoke in middle of night with eye pain.  Went to Ophthalmologist, who diagnosed patient with Ocular Sclerosis.  Uncertain if related to vaccination but concern with relation of ocular sclerosis to immune disorders feel like event should be reported.
Report 2000032935-1 describes vomiting in a 49 year old female who received a hepatitis-B vaccine. The vaccinee has no known drug allergies and no medical history. She takes conjugated estrogen/medoxyprogrestrone acetate. On 15-SEP-00 and 16-Oct-00, the vaccinee received her first and second 1 cc left deltoid doses of the hepatitis-B vaccine, respectively.  On 16-Oct-00, within a few hours post vaccination with the hepatitis-B vaccine, the vaccinee experienced nausea. By 17-Oct-00 AM, the vaccinee experienced nausea and vomiting and had a headache. On 18-Oct-00, the vaccinee had fever and chills for a total of two days. the vaccinee missed 1 1/2 days of work. By 23-Oct-oo, her symptoms had revealed. As of 10-Nov-00, the outcome of the events is resolved.
Headache, dizziness, fatigue, extreme nausea, vomiting,  diarrhea, body aches,  chills - symptoms intensified 12/29/2021
Shortness of breath and tremors with Pfizer-BioNTech covid-19 vaccine 25 minutes after 0.3 mL IM for right deltoid after first dose.  Hemodynamically stable and afebrile. Differential diagnosis includes but is not limited to allergic reaction, anxiety, panic attack, asthma attack, sequelae of hyperthyroidism. After resting comfortably in the room for approximately 15 minutes, she reported that her symptoms were starting to subside. She happily excepted diphenhydramine (dose not documented). She was observed for 2.5 hours and had no worsening of symptoms. Her vital signs were stable and she had appropriate SPO2 on room air throughout her stay in the emergency department. We discussed strict return precautions for evidence of allergic reaction, chest pain, worsening shortness of breath, altered mental status or fever. She will follow-up with her primary care doctor. Discharged in stable condition to the care of her husband.
Pt noticed a rash upper left arm the morning of 09/08/03, no itching. This rash was verified by RN 09/10/03. A few areas of rash were noted on back. Currently has rash left arm and back.
Dizziness room spinning; Vomiting; Low grade  fever; A spontaneous report was received from a consumer concerning a 78-years-old female patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced events dizziness room spinning, vomiting, low grade fever.  The patient's medical history was not provided. No relevant concomitant medications were reported.  On 27 Jan 2021, prior to the onset of the events the patient received first of two planned doses of mRNA-1273 (lot/batch: 032L20A) intramuscularly for prophylaxis of COVID-19 infection.  On an unknown date, the patient experienced the event(s) Dizziness room spinning, Vomiting, Low grade fever.  No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not reported.   The outcome of event(s), dizziness room spinning, vomiting, low grade fever was unknown.
Left arm totally disabled, unable to move in any position without severe pain, severe pain subsided after 48 hours but could not push, pull or raise arm above chest level. Pain continues to persist at various intervals and all movements are restricted. Reported history to clinic on 1/6/16. Suspect problem was improper injection procedure causing severe nerve damage, prognosis for recovery unknown at this time. PCV 13 vaccine and/or unknown allergy not suspect.
Four days after receiving the vaccine, I started having disturbing dreams every night. I wake up between 2 and 5 am with high anxiety related to the dreams.  This has been happening regularly and it disturbs my sleep and increases my stress and anxiety.